SLC5A2 and metabolic dysfunction-associated steatotic liver disease: Although no liver-targeting pharmacotherapeutics against NAFLD are presently in use, current drugs, such as metformin [81], GLP1R agonists [3] and SGLT2 inhibitors [4], being clinically used for the treatment of other metabolic diseases (i.e., diabetes), have shown benefits in alleviating different aspects of NAFLD pathology [4,82].